16mg retatrutide Promises Big Weight Loss, but Safety Remains a Question Retatrutide Phase 3: 60% Achieved

Retatrutide: Phase 2 data showed A1c reductions of 1.5-2.0%, with the glucagon component adding complexity to blood sugar management

For women with PCOS considering future treatment, this pattern is similar to what has been observed with existing weight loss treatments in this class

These improper listings can delay generic drug competition as a result of triggering automatic litigation stays, increase litigation costs that could disincentivize the development of generic drugs, and increase costs across the healthcare system

Paid subscribers can download it for free in the subscriber chat.

Proactive documentation: Build the PA case over multiple visits, not just at the point of prescribing

Zhang et al., 2024)